title: Crizotinib administered via nasogastric and percutaneous endoscopic gastrostomy tubes for the successful treatment of ALK-rearranged lung cancer in a patient with poor performance status.
abstract: Crizotinib-an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-is effective in non-small-cell lung cancers (NSCLCs) that express ALK. Here, we report a patient with ALK-positive lung adenocarcinoma who was administered crizotinib via nasogastric and percutaneous endoscopic gastrostomy (PEG) tubes, with positive results. This case indicates that patients with ALK-positive NSCLC may successfully be treated with crizotinib via nasogastric or PEG tubes. This approach can even be used as a salvage treatment in patients with poor prognoses.
authors.affiliation: Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan. tamaik@kcho.jp
authors.forename: Koji
authors.initials: K
authors.lastname: Tamai
authors.forename: Kazuma
authors.initials: K
authors.lastname: Nagata
authors.forename: Kyoko
authors.initials: K
authors.lastname: Otsuka
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nakagawa
authors.forename: Ryo
authors.initials: R
authors.lastname: Tachikawa
authors.forename: Kojiro
authors.initials: K
authors.lastname: Otsuka
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Katakami
authors.forename: Keisuke
authors.initials: K
authors.lastname: Tomii
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics*; D000284:Administration, Oral; D000368:Aged; D000077548:Anaplastic Lymphoma Kinase; D000077547:Crizotinib; D004750:Enteral Nutrition; D005260:Female; D005773:Gastroscopy; D005774:Gastrostomy / Q000379:methods*; D015870:Gene Expression; D015321:Gene Rearrangement / Q000235:genetics*; D006801:Humans; D007441:Intubation, Gastrointestinal; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D058990:Molecular Targeted Therapy; D015514:Oncogene Proteins, Fusion; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D011720:Pyrazoles / Q000008:administration & dosage*; D011725:Pyridines / Q000008:administration & dosage*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics*; D016879:Salvage Therapy
chemical_list: C522504:EML4-ALK fusion protein, human; D015514:Oncogene Proteins, Fusion; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases